Celadon Pharmaceuticals Grapples with Funding Uncertainty While Operations Continue

 

Celadon Pharmaceuticals Plc (LSE:CEL) has disclosed ongoing difficulties in accessing funds from its secured credit facility, with no material progress since its previous update. The company is actively pursuing alternative financing strategies but remains uncertain about its ability to secure the necessary capital. Despite tight working capital, continued support from creditors has enabled Celadon to maintain operations into May 2025. However, without timely access to new funding, the company warns that it could face the risk of entering administration, potentially affecting all stakeholders.

Company Profile: Celadon Pharmaceuticals Plc

Based in the UK, Celadon Pharmaceuticals is focused on the development and commercialization of cannabis-based medicines, primarily targeting chronic pain management. The company also explores therapeutic applications for conditions such as autism. Its operations are centered around a 100,000-square-foot EU-GMP-certified facility, featuring indoor hydroponic cultivation, GMP extraction capabilities, and dedicated research labs. Celadon holds a Home Office license for the commercial supply of medicinal cannabis and is conducting a clinical trial for cannabis treatments addressing chronic pain. Additionally, the company has an equity interest in Kingdom Therapeutics, which is advancing cannabinoid therapies for autism.

• Year-to-Date Share Performance: -56.67%

• Average Daily Volume: 258,672 shares

• Technical Sentiment: Buy

• Current Market Capitalisation: £4.47 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  London Academy Of Trading

• 

  Tip TV

• 

  Ben Branson

• 

  Matthew Davison